NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Institute of Medicine (US). Addressing the Threat of Drug-Resistant Tuberculosis: A Realistic Assessment of the Challenge: Workshop Summary. Washington (DC): National Academies Press (US); 2009.

Cover of Addressing the Threat of Drug-Resistant Tuberculosis

Addressing the Threat of Drug-Resistant Tuberculosis: A Realistic Assessment of the Challenge: Workshop Summary.

Show details

Forum on Drug Discovery, Development, and Translation1

Gail H. Cassell (Co-Chair), Eli Lilly and Company, Indiana

Jeffrey M. Drazen (Co-Chair), New England Journal of Medicine, Massachusetts

Barbara Alving, National Center for Research Resources, Maryland

Hal Barron, Genentech, California

Leslie Z. Benet, University of California, San Francisco

Catherine Bonuccelli, AstraZeneca Pharmaceuticals, Delaware

Linda Brady, National Institute of Mental Health, Maryland

Robert M. Califf, Duke University Medical Center, North Carolina

Scott Campbell, American Diabetes Association, Virginia

C. Thomas Caskey, University of Texas-Houston Health Science Center

Peter B. Corr, Celtic Therapeutics, New York

James H. Doroshow, National Cancer Institute, Maryland

Paul R. Eisenberg, Amgen, Inc., California

Gary L. Filerman, Atlas Research, Virginia

Garret A. FitzGerald, University of Pennsylvania School of Medicine

Elaine K. Gallin, The Doris Duke Charitable Foundation, New York

Steven K. Galson, Office of the Surgeon General, U.S. Department of Health and Human Services, Maryland

Mikhail Gishizky, Entelos, Inc., California

Stephen Groft, National Institutes of Health, Maryland

Edward W. Holmes, National University of Singapore

Peter K. Honig, Merck & Co., Inc., Pennsylvania

A. Jacqueline Hunter, GlaxoSmithKline, United Kingdom

Michael Katz, March of Dimes Foundation, New York

Jack D. Keene, Duke University Medical Center, North Carolina

Ronald L. Krall, GlaxoSmithKline, Pennsylvania

Freda Lewis-Hall, Pfizer, Inc., New York

William D. Matthew, National Institute of Neurological Disorders and Stroke, Maryland

Musa Mayer,, New York

Mark B. McClellan, Brookings Institution, Washington, DC

Carol Mimura, University of California, Berkeley

John Orloff, Novartis Pharmaceuticals Corporation, New Jersey

Amy P. Patterson, National Institutes of Health, Maryland

Janet Shoemaker, American Society for Microbiology, Washington, DC

Lana Skirboll, National Institutes of Health, Maryland

Nancy S. Sung, Burroughs Wellcome Fund, North Carolina

Irena Tartakovsky, Association of American Medical Colleges, Washington, DC

Jorge A. Tavel, National Institute of Allergy and Infectious Diseases, Maryland

Joanne Waldstreicher, Johnson & Johnson, New Jersey

Janet Woodcock, U.S. Food and Drug Administration, Maryland

Raymond L. Woosley, Critical Path Institute, Arizona



IOM forums and roundtables do not issue, review, or approve individual documents. The responsibility for the published workshop summary rests with the workshop rapporteurs and the institution.

Copyright © 2009, National Academy of Sciences.
Bookshelf ID: NBK44994


  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (12M)

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...